ClinicalTrials.gg
CompletedNCT00509262Updated May 12, 2017Results posted

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)

A Phase 3 interventional study of Sitagliptin and Glipizide in Diabetes Mellitus, Type 2 and Renal Insufficiency, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2017-05-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
426
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
42nd of 197
426 · median 102
Started
2007
with 16 others
Phase 3
74 of 198
none open now
Registered
30th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 42nd largest by enrollment of the 197 interventional ones that give a count, is one of 17 that started in 2007, is one of 74 in phase 3, and was the 30th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of the study is to compare how sitagliptin and glipizide lower blood glucose levels in participants with moderate or severe renal insufficiency.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Renal Insufficiency, Chronic
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has type 2 diabetes mellitus
  • Has moderate or severe renal insufficiency

Exclusion criteria

Exclusion Criteria:

  • Has type 1 diabetes mellitus or a history of ketoacidosis
  • Is on a new weight loss program
  • Has active liver disease
  • Is on dialysis or is likely to need dialysis during the study
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
426 participants (actual)

Study arms

  • Experimental
    Sitagliptin

    Sitagliptin + Placebo for Glipizide

    Drug: Sitagliptin · Drug: Placebo for Glipizide

  • Active comparator
    Glipizide

    Glipizide + Placebo for Sitagliptin

    Drug: Glipizide · Drug: Placebo for Sitagliptin

Interventions

  • Participants with moderate renal insufficiency will receive two sitagliptin 25 mg tablets orally daily; participants with severe renal insufficiency will receive one sitagliptin 25 mg tablet orally daily

    Also known as: MK-0431, Januvia

  • Participants will receive glipizide 2.5 mg (1/2 tablet) orally once daily up to 20 mg orally daily (10 mg twice daily)

    Also known as: Glucotrol

  • DrugPlacebo for Sitagliptin

    Participants with moderate renal insufficiency will receive 2 placebo for sitagliptin tablets orally daily; participants with severe renal insufficiency will receive 1 placebo for sitagliptin tablet orally daily

  • DrugPlacebo for Glipizide

    Participants will receive 1/2 tablet of placebo for glipizide orally once daily up to 2 tablets orally twice daily

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (A1C) Levels at Week 54

    A1C represents percentage of glycosylated hemoglobin.

    Time frame: Baseline to Week 54

  2. Percentage of Participants With Hypoglycemic Events

    Percentage of participants with at least one symptomatic hypoglycemic adverse event, excluding data after initiation of glycemic rescue therapy.

    Time frame: Baseline up to 28 days following the last dose of study therapy

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 54

    Time frame: Baseline to Week 54

  2. Change From Baseline in Body Weight at Week 54

    Time frame: Baseline to Week 54

07

Results

Posted Mar 28, 2012

Participant flow

Participant flow — Overall Study
MilestoneSitagliptinGlipizide
Started211212
Completed164170
Not completed4742
Withdrew: Adverse event1618
Withdrew: Other22
Withdrew: Lack of efficacy10
Withdrew: Lost to follow-up16
Withdrew: Physician decision13
Withdrew: Protocol violation22
Withdrew: Withdrawal by subject2411

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (A1C) Levels at Week 54

A1C represents percentage of glycosylated hemoglobin.

Time frame:
Baseline to Week 54
Reported as:
Mean · Percent of glycosylated hemoglobin
Change From Baseline in Hemoglobin A1c (A1C) Levels at Week 54
Percent of glycosylated hemoglobinSitagliptinGlipizide
Baseline7.76 ± 0.657.79 ± 0.70
Change from Baseline at Week 54-0.70 ± 0.80-0.62 ± 0.91
Statistical analysis
  • Sitagliptin vs Glipizide · ANCOVA · Difference in least squares mean: -0.11 · 95% CI -0.29 to 0.06Based on analysis of covariance with terms for treatment, renal insufficiency stratum at Visit 4/Week -2 (moderate, or severe), prior diabetes pharmacotherapy (on or not on oral antihyperglycemic agent), and a covariate for baseline A1C.
PrimaryPercentage of Participants With Hypoglycemic Events

Percentage of participants with at least one symptomatic hypoglycemic adverse event, excluding data after initiation of glycemic rescue therapy.

Time frame:
Baseline up to 28 days following the last dose of study therapy
Reported as:
Number · percentage of participants
Percentage of Participants With Hypoglycemic Events
percentage of participantsSitagliptinGlipizide
Percentage of Participants With Hypoglycemic Events6.217.0
Statistical analysis
  • Sitagliptin vs Glipizide · Miettirnen& Nurminen method · p = 0.001 · Mean difference (final values): -10.8 · 95% CI -17.1 to -4.8Miettirnen \& Nurminen method stratified by renal insufficiency stratum at Visit 4/Week -2 (moderate or severe) \& prior diabetes pharmacotherapy
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 54
Time frame:
Baseline to Week 54
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 54
mg/dLSitagliptinGlipizide
Baseline148.6 ± 39.9143.9 ± 35.7
Change from Baseline at Week 54-16.7 ± 47.1-20.2 ± 48.6
Statistical analysis
  • Sitagliptin vs Glipizide · ANCOVA · Difference in least squares mean: 7.1 · 95% CI -1.9 to 16.1Analysis of covariance with terms for treatment, renal insufficiency stratum at Visit 4/Week -2 (moderate or severe), prior diabetes pharmacotherapy (on or not on oral antihyperglycemic agent), and a covariate for baseline Fasting Plasma Glucose.
SecondaryChange From Baseline in Body Weight at Week 54
Time frame:
Baseline to Week 54
Reported as:
Least squares mean · kg
Change From Baseline in Body Weight at Week 54
kgSitagliptinGlipizide
Change From Baseline in Body Weight at Week 54-0.6 ± 0.31.2 ± 0.3
Statistical analysis
  • Sitagliptin vs Glipizide · ANCOVA · p = <0.001 · Difference in least squares mean: -1.8 · 95% CI -2.6 to -1.0Analysis of covariance with terms of treatment, renal insufficiency stratum at Visit 4/Week -2 (moderate or severe), prior diabetes pharmacotherapy (on or not on oral antihyperglycemic agent), and a covariate for baseline body weight.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin—36/210 (17.1%)69/210 (32.9%)
Glipizide—38/212 (17.9%)89/212 (42%)
Most frequent serious events
Showing 10 of 73
Most frequent serious events
EventSitagliptinGlipizide
HypoglycaemiaMetabolism and nutrition disorders1/2104/212
Urinary tract infectionInfections and infestations3/2101/212
Cardiac failure congestiveCardiac disorders0/2103/212
Myocardial infarctionCardiac disorders2/2101/212
Cerebrovascular accidentNervous system disorders2/2101/212
Benign prostatic hyperplasiaReproductive system and breast disorders2/2100/212
Acute myocardial infarctionCardiac disorders1/2102/212
Cardiac failureCardiac disorders0/2102/212
Renal failure acuteRenal and urinary disorders1/2102/212
Renal failure chronicRenal and urinary disorders1/2102/212
Most frequent other events
Most frequent other events
EventSitagliptinGlipizide
HypoglycaemiaMetabolism and nutrition disorders12/21035/212
Blood glucose decreasedInvestigations15/21032/212
Urinary tract infectionInfections and infestations11/21020/212
Oedema peripheralGeneral disorders15/21010/212
Upper respiratory tract infectionInfections and infestations10/21015/212
DiarrhoeaGastrointestinal disorders11/21012/212
HypertensionVascular disorders11/2106/212
DizzinessNervous system disorders7/21011/212

Baseline characteristics

Age, Continuous
Age, Continuous(years)SitagliptinGlipizideTotal
Mean64.2 ± 10.764.2 ± 9.464.2 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)SitagliptinGlipizideTotal
Female8090170
Male131122253
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Arjona Ferreira JC, Marre M, Barzilai N, Guo H, Golm GT, Sisk CM, Kaufman KD, Goldstein BJ. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care. 2013 May;36(5):1067-73. doi: 10.2337/dc12-1365. Epub 2012 Dec 17. PubMed 23248197 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2007 to primary completion in Mar 2011, 41 months.

Results were first posted in Mar 2012, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 41 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2007
First posted
Jul 31, 2007
StartActual
Oct 9, 2007
Primary completionActual
Mar 16, 2011
CompletionActual
Mar 16, 2011
Results first posted
Mar 28, 2012
Last update
May 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00509262
Responsible party
Sponsor
First posted
Jul 31, 2007
Start date
Oct 9, 2007
Primary completion
Mar 16, 2011
Completion
Mar 16, 2011
Results posted
Mar 28, 2012
Last update
May 12, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion